CICC: Maintains Beautiful Countryside Medical Health Outperform Industry Rating, Raises Target Price to HKD 40

CICC released a research report stating that it maintains the profit forecast for Beijitianyuan Medical Health in 2025-2026 unchanged, with the current stock price corresponding to a 25-26 year P/E ratio of 25/21x. It maintains an outperform industry rating, based on the company's outstanding business model advantages and the opening up of internal and external long-term space. The target price has been raised by 8% to 40 Hong Kong dollars, corresponding to a 25-26 year P/E ratio of 31/27x, with a potential upside of 21%.